Group items tagged

If there is one area guaranteed to confuse many traders and lead to multiple opinions on the most appropriate approach, it is the subject of stop losses. The science and the art of placing stops is featured extensively in many trading books and guides, but the bottom line is that there is no right or wrong answer, simply the fact that stop losses must be used to limit potential downside exposure when trading. Traders should also be careful not to confuse stop losses with buy stops, which trigger an opening position rather than closing the trade. It is very important not to package together the placing of stops with money management, as the two represent different strands of trading. Simply put, stops are there to protect profits and limit the potential downside at any time once a trade has been opened, and are part of an exit strategy for trades that are already open. Money management covers position sizing or amounts to be risked within each trade of a portfolio.

good stuff http://mcx-silver-gold-tips.blogspot.in/2015/07/share-market-tips-gold-recovers-its.html

The reversal in the markets seemed inverse today as the stocks with the most exposure to current global challenged regained much of the previous day's losses and basic materials and other more distance investments hovered near lows.

RR Investor offers you to Protect Your Investment by investing in HDFC Capital Protection Oriented Fund Series-III Salient Features A close-ended capital protection oriented income scheme with tenure of 1100 days. The Scheme will have a portfolio mix of highest rated debt and money market instruments along with exposure to equities and equity-related instruments. The portfolio of the Scheme will be structured in a manner to protect your original investment with a potential for capital appreciation over the tenure of this scheme. So, consider investing.

This article discusses a handful of penny stocks with exposure to potential Alzheimer's disease treatments. The bullish sympathy trend has come to light following late-breaking news on Tuesday that Biogen (NASDAQ: BIIB) and Eisai Co.'s experimental Alzheimer's drug significantly slowed the progression of the disease in a large study. The 18-month, Phase 3 study of 1,800 patients tested the treatment on early-stage Alzheimer's patients. 4 more Alzheimer's stocks to watch

Treasury yields have fallen below S&P 500 dividend yields, which occurs rarer than a Blue Moon. S&P's Stovall says historically, stocks have moved significantly higher 12 months later.